NCT01672918 is a clinical trial in Autoimmune Lymphoproliferative Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT01672918?

NCT01672918 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT01672918 study?

NCT01672918 studies Autoimmune Lymphoproliferative Syndrome, Lymphoma.

Is NCT01672918 still recruiting?

NCT01672918 is currently withdrawn. Last updated 5 December 2019.

Last reviewed 2019-12-05 · How we verify

NCT01672918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorodeoxyglucose Imaging Studies to Detect Lymphoma

Withdrawn Last updated 5 December 2019

What this trial tests

trial in Autoimmune Lymphoproliferative Syndrome. Withdrawn.

Timeline

6 August 2012

27 February 2015

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	6 August 2012
Estimated completion	27 February 2015

Conditions studied

Autoimmune Lymphoproliferative Syndrome — all drugs for Autoimmune Lymphoproliferative Syndrome →
Lymphoma — all drugs for Lymphoma →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 5 to 99, any sex, with Autoimmune Lymphoproliferative Syndrome or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: \- Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the lymph system. People with ALPS often have swollen lymph nodes, especially in the neck and armpit. They also have a much higher risk of developing lymphoma. It is not always easy to determine whether the swollen lymph nodes are caused by ALPS or by lymphoma. Researchers want to see whether different imaging studies can show the difference between ALPS and lymphoma. The studies used will be positron emission tomography (PET) and computed tomography (CT). Researchers will use a drug called fluorodeoxyglucose (FDG) to look at the lymph nodes. Objectives: \- To see how well imaging studies can distinguish between swollen lymph nodes caused by ALPS or by lymphoma. Eligibility: * Individuals must be 5 years of age or older and enrolled on the National Institutes of Health natural history study of ALPS. * Participants should either have lymphoma or have symptoms that suggest possible lymphoma. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have an FDG-PET/CT scan. It will be performed according to standard procedures. * If the results of the scan do not show lymphoma, participants will stay on the study for 1 year for clinical follow up. They may have a second FDG-PET/CT scan if there is a change in symptoms. Such changes include further enlargement of lymph nodes, unexplained fevers, or weight loss. * If the results of the scan show evidence of new or worsening lymphoma, treatment on this study will end. Further tests based on clinical symptoms, including a lymph node biopsy, may be done under the ALPS natural history study to rule out or make a diagnosis of lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autoimmune Lymphoproliferative Syndrome

Currently open trials in the same condition.

NCT06730126 — Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoprolife · Phase 2 · recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01672918 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 5 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01672918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing